Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology

BMC Nephrol. 2023 Sep 20;24(1):278. doi: 10.1186/s12882-023-03326-8.

Abstract

Background: Thrombotic microangiopathies (TMAs) are rare but can be severe in kidney transplant. recipients (KTR).

Methods: We analysed the epidemiology of adjudicated TMA in consecutive KTR during the. 2009-2021 period.

Results: TMA was found in 77/1644 (4.7%) KTR. Early TMA (n = 24/77 (31.2%); 1.5% of all KTR) occurred during the first two weeks ((median, IQR) 3 [1-8] days). Triggers included acute antibody-mediated rejection (ABMR, n = 4) and bacterial infections (n = 6). Graft survival (GS) was 100% and recurrence rate (RR) was 8%. Unexpected TMA (n = 31/77 (40.2%); 1.5/1000 patient-years) occurred anytime during follow-up (3.0 (0.5-6.2) years). Triggers included infections (EBV/CMV: n = 10; bacterial: n = 6) and chronic active ABMR (n = 5). GS was 81% and RR was 16%. Graft-failure associated TMA (n = 22/77 (28.6%); 2.2% of graft losses) occurred after 8.8 (4.9-15.5) years). Triggers included acute (n = 4) or chronic active (n = 14) ABMR, infections (viral: n = 6; bacterial: n = 5) and cancer (n = 6). 15 patients underwent transplantectomy. RR was 27%. Atypical (n = 6) and typical (n = 2) haemolytic and uremic syndrome, and isolated CNI toxicity (n = 4) were rare. Two-third of biopsies presented TMA features.

Conclusions: TMA are mostly due to ABMR and infections; causes of TMA are frequently combined. Management often is heterogenous. Our nosology based on TMA timing identifies situations with distinct incidence, causes and prognosis.

Keywords: Hemolytic uremic syndrome; Infection; Kidney transplantation; Malignant hypertension; Outcomes.

MeSH terms

  • Antibodies
  • Azotemia*
  • Biopsy
  • Humans
  • Kidney Transplantation* / adverse effects
  • Thrombotic Microangiopathies* / epidemiology
  • Thrombotic Microangiopathies* / etiology

Substances

  • Antibodies